Lennham Pharmaceuticals utilizes deuterium chemistry to enhance the metabolic and pharmacological profiles of existing drugs, improving their efficacy and safety. By modifying chemical compounds, the company generates data that supports broad patent protection and advances products with a high likelihood of clinical success.
Funding
$3.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many existing drugs have limitations in their metabolic and pharmacological profiles, leading to suboptimal efficacy, safety concerns, and limited patent protection. Improving these profiles can lead to better patient outcomes and new market opportunities.
Solution
Lennham Pharmaceuticals leverages deuterium chemistry to modify existing chemical compounds, enhancing their metabolic and pharmacokinetic properties. By selectively replacing hydrogen atoms with deuterium, Lennham aims to improve drug efficacy, reduce toxicity, and extend patent life. The company focuses on generating robust experimental data to support broad patent protection for its novel deuterated drug candidates. This approach increases the likelihood of clinical success and commercial viability for improved pharmaceutical products.
Target Audience
Lennham's primary target audience includes pharmaceutical companies seeking to improve existing drug products, as well as investors interested in innovative drug development opportunities.
Features
- Deuterium modification of existing drugs to improve metabolic stability and reduce the rate of clearance.
- Enhanced pharmacokinetic properties, such as increased bioavailability and prolonged half-life.
- Generation of experimental data to support patent applications for novel deuterated compounds.
- Focus on improving drug efficacy and safety profiles through targeted deuterium substitution.